查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2042519

融合切片檢查市場：市場洞察、競爭格局和市場預測（2034 年）

Fusion Biopsy - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

融合切片檢查市場概述

  • 全球融合切片檢查市場預計將從 2025 年的 7.9836 億美元成長到 2034 年的 15.1232 億美元，展現出強勁且持續的成長動能。
  • 全球融合切片檢查市場預計在 2026 年至 2034 年的預測期內將以 7.40% 的複合年成長率成長。
  • 融合切片檢查市場的發展受到多種因素的共同推動：前列腺癌病例的增加、對精準早期診斷日益成長的需求、磁振造影(MRI) 和超音波影像等影像技術的不斷進步，以及公眾意識的提高和篩檢項目的擴展。隨著攝護腺癌發生率的上升，對能夠早期發現具有臨床意義腫瘤的精準診斷方案的需求也日益成長。同時，公眾意識的提升和廣泛的篩檢（包括 PSA 檢測和 MRI 檢查）使得尋求明確診斷的患者數量不斷增加。融合切片檢查透過將先進的影像技術與標靶取樣相結合，滿足了這些需求，提高了診斷的準確性，並減少了不必要的檢查。這些因素共同推動了融合切片檢查系統在醫療機構中的應用，並促進了整體市場的成長。
  • 在融合切片檢查市場中營運的主要公司包括 Koninklijke Philips NV、KOELIS SA、innoMedicus Ltd.、Siemens Healthineers AG、MedCom GmbH、Exact Imaging Inc.、Focal Healthcare Inc.、Biobot Surgical Pte. Ltd.、Esaote SpA、GE HealthCare Technologies Inc.、Hita, Medical Technologies Inc. Inc.、Eigen, Inc.、UroMedTech GmbH 和 D&K Technologies Pvt. Ltd.。
  • 由於北美擁有先進的醫療基礎設施、磁振造影(MRI) 和切片檢查等創新超音波影像技術的普及率高，以及前列腺癌發病率不斷上升，預計北美將成為融合活體組織切片市場的主要驅動力。此外，主要市場參與者的存在、完善的保險報銷機制以及人們對早期準確癌症診斷重要性的日益重視，都進一步推動了融合切片檢查系統在全部區域的應用。
  • 預計到 2025 年，融合切片檢查市場中配件類別將佔最大的市場佔有率。

促進融合切片檢查市場成長的因素

  • 前列腺癌發生率上升推動融合切片檢查應用激增：主要促進因素之一是全球前列腺癌發病率的上升。人口老化、生活方式的改變以及篩檢計畫的改進，都提高了診斷率。融合切片檢查在準確檢測具有臨床意義的腫瘤方面發揮著至關重要的作用，因此被泌尿系統和醫療保健專業人員廣泛採用。
  • 精準早期診斷的需求日益成長：傳統切片檢查方法由於隨機取樣，常常漏診重要病灶。融合切片檢查結合了磁振造影（MRI）和超音波，顯著提高了標靶檢測的準確性。對更精確診斷和減少假陰性結果的需求，正在加速向融合影像引導技術的轉變。
  • 影像技術的進步：磁振造影（MRI）和超音波影像成像技術的快速發展，實現了高解析度成像，使病灶的顯示更加清晰。這些技術透過軟體平台的整合，提高了切片檢查的準確性，並推動了市場成長。

融合切片檢查市場報告細分

本融合切片檢查市場報告全面概​​述了全球融合切片檢查市場，揭示了關鍵趨勢、成長要素、挑戰和機會。報告詳細分析了市場細分，包括產品（儀器、耗材及配件）、切片檢查途徑（經直腸和經會陰）、最終用戶（醫院、影像中心及其他機構）和地區。報告深入分析了北美、歐洲和亞太等主要市場的競爭格局、監管環境和市場動態。報告詳細介紹了主要產業參與者及其最新產品創新，為企業提供關鍵數據，幫助其識別市場潛力、制定策略規劃，並掌握快速成長的融合切片檢查市場中的新興機會。

融合切片檢查是一種先進的診斷方法，它結合了磁振造影（MRI）和超音波影像等影像技術，能夠精確識別和收集可疑組織，主要用於前列腺癌的檢測。透過在檢查過程中將預先記錄的MRI影像與即時超音波影像疊加，可以對特定病灶進行靶向切片檢查，與傳統的隨機切片檢查相比，提高了活體組織切片的準確性，並增加了發現具有臨床意義的癌症的可能性。

融合切片檢查市場的發展受到多種因素的共同推動：前列腺癌病例的增加、對精準早期診斷日益成長的需求、磁振造影（MRI）和超音波影像等影像技術的不斷進步，以及篩檢意識的提高和篩檢項目的擴展。尤其是在高齡化社會，隨著全球前列腺癌發生率的持續上升，迫切需要能夠早期識別具有臨床意義的腫瘤並進行治療的精準診斷方案。傳統的切片檢查方法由於隨機取樣，容易出現漏診和過度診斷，因此，對融合切片檢查等更具針對性的方法的需求日益成長。

同時，宣傳活動的擴大、政府主導的篩檢計畫以及PSA檢測和基於MRI的評估的廣泛應用，促使接受診斷程序的患者人數不斷增加。患者數量的增加直接推動了對能夠提供更高準確性和可靠性的先進切片檢查技術的需求。融合切片檢查透過將高解析度影像與即時引導相結合，有效應對了這些挑戰，使臨床醫生能夠精準定位可疑病灶，提高癌症檢出率，並最大限度地減少不必要的切片檢查和重複活體組織切片。

此外，包括軟體平台整合、3D成像和人工智慧標靶識別在內的持續技術創新，正在提高手術效率和臨床療效。這些創新不僅增強了醫師的信心，也有助於更恰當的病患管理和治療方案。這些因素共同推動了融合切片檢查系統在醫院和診斷中心的應用，從而顯著促進了整體市場成長。

融合切片檢查市場的最新市場動態和趨勢是什麼？

全球前列腺癌負擔日益加重，大大推動了融合切片檢查市場的整體發展。

根據國際癌症研究機構（IARC）2026年發布的數據，預計到2030年，全球新增前列腺癌病例將達到1,829,988例。雖然前列腺特異性抗原（PSA）篩檢的廣泛應用已發現大量疑似病例，但傳統的隨機切片檢查方法可能無法準確檢測出具有臨床意義的腫瘤，或導致對生長緩慢的癌症過度診斷。這項限制促使人們迫切需要更準確、更可靠的診斷技術。融合切片檢查結合了磁振造影（MRI）和超音波影像影像技術，能夠對MRI識別出的可疑病灶進行靶向取樣，從而顯著提高高侵襲性癌症的檢出率，同時減少不必要的切片檢查。

此外，擴大宣傳活動和早期篩檢措施在融合切片檢查市場成長中發揮至關重要的作用，它們促進了患者參與癌症篩檢並提高了診斷準確性。美國癌症協會和國家癌症研究所等機構進行的前列腺癌宣傳宣傳活動鼓勵男性，尤其是高風險族群，定期進行PSA檢測和臨床評估。

此外，產品研發活動的活性化和政府主導的措施也進一步推動了融合切片檢查市場的整體發展。例如，2024年7月，致力於打造個人化前列腺癌治療未來的AI醫療公司Avenda Health宣布，美國醫學會（AMA）已引入第三類現行醫療程序術語（CPT）代碼0898T，以方便醫保報銷先進的AI輔助前列腺癌定位技術。因此，上述因素預計將在預測期內推動融合切片檢查市場的整體擴張。

然而，來自其他診斷技術的競爭正在限制融合切片檢查市場的發展，這些技術提供了創傷更小、更快、有時更經濟的癌症檢測方案。諸如液態生物檢體和使用磁振造影(MRI) 的先進影像學方法等新興技術正日益受到關注，因為它們減少了侵入性組織取樣的需求。這些方法可以透過血液樣本檢測癌症生物標記，並提供高解析度的影像訊息，從而最大限度地減少患者的不適感和手術相關風險。隨著醫療保健系統越來越重視以患者為中心且經濟高效的診斷方法，這些替代方法的日益普及可能會降低對融合切片檢查技術的依賴，並最終阻礙市場成長。

融合切片檢查市場細分分析

融合切片檢查市場：按產品（設備、耗材和配件）、按切片檢查途徑（經直腸和經會陰）、按最終用戶（醫院、診斷影像中心、其他）、按地區（北美、歐洲、亞太地區、世界其他地區）分類

融合切片檢查市場區域分析

北美融合切片檢查市場趨勢

預計到2025年，北美將佔融合切片檢查市場42.67%的最大佔有率，成為所有地區中市場佔有率最高的地區。北美有望成為融合活體組織切片市場的主要驅動力，這得益於其先進的醫療基礎設施、磁振造影（MRI）和超音波影像等創新成像技術的高普及率以及前列腺癌發病率的不斷上升。此外，主要市場參與者的存在、完善的保險切片檢查體係以及人們對早期準確癌症診斷重要性的日益重視，都進一步推動了融合切片檢查系統在全部區域的應用。

根據零前列腺癌組織（2026 年）提供的數據，預計 2026 年將有約 333,830 例新增前列腺癌病例。同一來源也指出，美國有超過 350 萬名前列腺癌倖存者。

融合切片檢查結合了磁振造影(MRI) 和超音波影像影像技術，能夠對 MRI 識別出的可疑病灶進行靶向取樣，從而顯著提高高侵襲性癌症的檢測率，同時減少不必要的切片檢查。此外，儘管先前切片檢查為陰性，但 PSA 水平持續升高的患者數量不斷增加，這進一步推動了融合切片檢查在北美的應用，因為它有助於識別先前漏診的病灶。腫瘤學領域向個人化和精準醫療的轉變也促使臨床醫生採用融合切片檢查等先進診斷工具，以更好地進行風險分層和製定治療方案。

然而，主要市場參與企業不斷活性化產品研發力度，進一步推動了整體市場的發展。例如，2025年7月，皇家飛利浦公司（Koninklijke Philips NV）的UroNav Fusion切片檢查和導航系統最新版本獲得了FDA 510(k)批准。該系統透過改善註釋工作流程和更精準的標靶化，增強了影像導引下的前列腺癌診斷能力。

預計這些因素將共同推動美國融合切片檢查市場在 2026 年至 2034 年的預測期內實現顯著成長。

歐洲融合切片檢查市場趨勢

歐洲融合切片檢查市場正經歷強勁且持續的成長，這主要得益於前列腺癌負擔的加重、先進診斷技術的日益普及以及領先醫療設備製造商在該地區的強大影響力。德國、英國和法國等國家正大力投資於精準切片檢查和成像基礎設施，加速融合活體組織切片系統的應用，該系統整合了磁振造影(MRI) 和超音波影像成像技術，用於靶向癌症檢測。此外，歐洲泌尿系統協會 (EAU) 的支持性臨床指南以及人們對早期診斷意識的提高，也進一步推動了市場擴張。該地區近期推出的產品創新和新產品也促進了市場成長。例如，2025 年 3 月，KOELIS 在歐洲泌尿系統協會 (EAU) 大會上宣布對其 Trinity® 融合切片檢查平台進行重大升級，重點在於最佳化工作流程並提高標靶切片檢查的準確性。此外，該公司於2024年9月推出了一款新型緊湊型3D換能器，旨在改進歐洲的經會陰融合切片檢查技術；並於2026年4月推出了人工智慧驅動的ProMap® Smart軟體，以簡化MRI-超音波融合工作流程並提高臨床效率。這種持續創新，加上臨床應用的不斷擴大和技術進步，正推動歐洲融合切片檢查市場強勁成長。

亞太地區融合切片檢查市場趨勢

由於醫療基礎設施的快速發展、人們對癌症早期檢測意識的提高以及中國、印度和日本等國家前列腺癌發病率的上升，亞太地區正成為融合切片檢查市場的主要驅動力。該地區正大力投資先進的診斷技術，特別是融合磁振造影(MRI) 和超音波影像，這些系統對於融合切片檢查至關重要。此外，政府主導的各項措施不斷擴大、醫療服務可近性的改善以及微創診斷方法的日益普及，都推動了對精準診斷工具的需求成長。日本和韓國等國家人口老化也進一步促進了市場成長，因為攝護腺癌的風險會隨著老齡化的成長而增加。

總體而言，醫療保健基礎設施的改善、技術的進步、疾病負擔的加重以及持續的產品創新正在加速亞太地區融合切片檢查系統的普及，使其成為全球市場成長最快的地區之一。

融合切片檢查市場的主要參與者有哪些？

以下是融合切片檢查市場的主要參與者。這些公司合計佔最大的市場佔有率，並引領產業趨勢。

  • Koninklijke Philips NV
  • KOELIS SA
  • innoMedicus Ltd.
  • Siemens Healthineers AG
  • MedCom GmbH
  • Exact Imaging Inc.
  • Focal Healthcare Inc.
  • Biobot Surgical Pte. Ltd.
  • Esaote SpA
  • GE HealthCare Technologies Inc.
  • Hitachi Medical Systems (Hitachi, Ltd.)
  • Canon Medical Systems Corporation
  • BK Medical Holding Company, Inc.,
  • igen, Inc.
  • UroMedTech GmbH
  • D&K Technologies Pvt. Ltd.
  • 其他

競爭格局如何影響融合切片檢查市場？

融合切片檢查市場的競爭格局瞬息萬變，儘管已呈現一定程度的集中化，但全球影像巨頭和專注於泌尿系統的專家共同推動著產業成長。皇家飛利浦、通用電氣醫療和KOELIS等領先企業憑藉其強大的先進影像和融合切片檢查系統產品組合佔了顯著的市場佔有率，而新興企業則專注於利基創新和區域擴張。

隨著各公司努力提高診斷準確率和簡化工作流程，競爭主要由持續的技術創新驅動，包括人工智慧整合、機器人輔助切片檢查和改進的磁振造影-超音波融合平台。同時，各公司積極推行產品發布、夥伴關係、併購和聯盟等策略性舉措，以加強其全球影響力並拓展新興市場。

此外，隨著新創企業推出經濟高效且先進的解決方案，而大型企業則利用其銷售網路和品牌影響力，競爭日趨激烈。這種平衡創造了一個競爭環境，促進了創新並加速了市場成長。總體而言，這種以技術進步、策略擴張和新參與企業增加參與企業特徵的不斷演變的競爭格局，正顯著影響著全球融合切片檢查技術的開發和應用。

融合切片檢查市場近期發展趨勢

  • 2026 年 4 月，KOELIS 發布了 ProMap® Smart 軟體，這是一款由人工智慧驅動的軟體，可簡化 MRI 和超音波融合工作流程，提高臨床效率。
  • 2025年7月，皇家飛利浦公司（Koninklijke Philips NV）的UroNav融合切片檢查和導航系統最新版本獲得FDA 510(k)批准。該系統透過改善註釋工作流程和更精確的標靶定位，增強了影像導引下的前列腺癌診斷。
  • 2025 年 3 月，牛津大學宣布推出一種新的 MRI-超音波融合切片檢查技術，旨在減少不必要的切片檢查，提高對具有臨床意義的前列腺癌的檢出率。
  • 2025 年 3 月，KOELIS 在歐洲泌尿系統協會 (EAU) 大會上宣布對其 Trinity® Fusion切片檢查平台進行高級改進，重點在於改進工作流程和提高靶向切片檢查的準確性。

融合切片檢查市場的市場細分

  • 產品特異性融合切片檢查
  • 裝置
  • 耗材和配件
  • 按切片檢查途徑分類的融合切片檢查市場規模
  • 經直腸
  • 會陰經
  • 融合切片檢查終端使用者應用領域
  • 醫院
  • 診斷影像中心
  • 其他
  • 融合切片檢查的區域市場趨勢
  • 北美融合切片檢查市場
  • 美國融合切片檢查市場
  • 加拿大融合切片檢查市場
  • 墨西哥融合切片檢查市場
  • 歐洲融合切片檢查市場
  • 英國融合切片檢查市場
  • 德國融合切片檢查市場
  • 法國融合切片檢查市場
  • 義大利融合切片檢查市場
  • 西班牙融合切片檢查市場
  • 其他歐洲融合切片檢查市場
  • 亞太地區融合切片檢查市場
  • 中國的融合切片檢查市場
  • 日本融合切片檢查市場
  • 印度融合切片檢查市場
  • 澳洲融合切片檢查市場
  • 韓國融合切片檢查市場
  • 亞太地區其他融合切片檢查市場
  • 世界其他地區的融合切片檢查市場
  • 南美洲融合切片檢查市場
  • 中東融合切片檢查市場
  • 非洲融合切片檢查市場

影響分析

人工智慧驅動的創新與應用：

人工智慧驅動的創新正在融合切片檢查的發展中發揮變革性作用，顯著提升了活體組織切片的準確性、效率和臨床決策能力。先進的人工智慧演算法正日益與磁振造影(MRI) 和超音波影像等影像技術相結合，尤其是在前列腺癌病例中，用於自動檢測、分割和分類可疑病灶。這些系統透過減少解讀差異並突出顯示需要靶向切片檢查的臨床重要區域來輔助放射科醫生。人工智慧也被用於即時影像融合最佳化，透過確保手術過程中 MRI 和超音波影像的精確對齊來提高穿刺針定位的準確性。此外，人工智慧驅動的預測分析和風險分層工具分析患者數據、影像學觀察和先前治療結果，以評估癌症惡性程度並支持制定個人化治療方案。人工智慧自動化透過縮短手術時間、最大限度地減少人為錯誤和提高操作者間的一致性，進一步簡化了工作流程。因此，人工智慧驅動的應用正在加速融合切片檢查系統的普及，不僅提高了診斷的信心，而且還實現了更準確、更有效率、以患者為中心的癌症治療。

美國關稅對融合切片檢查市場的影響分析：

美國關稅對融合切片檢查市場的影響總體上是負面的，該市場嚴重依賴先進的醫療設備和成像系統，並構成重大的經濟限制。融合切片檢查系統依賴磁振造影(MRI) 和超音波影像成像等昂貴設備，其中許多設備產自世界各地或從世界各地採購。近期美國關稅政策，包括2025年4月生效的關稅上調（包括約10%的基準關稅以及針對特定國家的更高關稅），正在推高進口醫療設備和組件的成本。因此，醫療機構面臨採購成本增加的困境，這可能會延遲對昂貴的整合切片檢查系統的資本投資。此外，由於美國使用的醫療設備約有70%產自海外，關稅對價格和供應也產生了顯著影響。

此外，關稅正在擾亂全球供應鏈，並為設備採購帶來不確定性，迫使醫院重新考慮或推遲購買先進的診斷技術。成本增加可能會轉嫁給患者，從而限制他們獲得融合切片檢查等先進技術的機會。為此，製造商被迫調整策略，例如將生產遷回國內或實現供應鏈多元化，這可能會增加營運複雜性並減緩創新步伐。總而言之，美國關稅正在造成成本壓力、供應鏈中斷和投資延遲，阻礙融合切片檢查技術在市場上的發展和應用。

這項分析能為客戶帶來哪些好處？

  • 成本管理：透過了解關稅趨勢，客戶可以預測成本上漲，並據此調整定價策略，以確保盈利。
  • 供應鏈最佳化：透過尋找替代供應商並使其供應鏈多元化，客戶可以減少對高關稅地區的依賴，並增強業務永續營運。
  • 監管合規：專家指導幫助客戶應對不斷變化的法規環境，從而保持合規並避免潛在的法律挑戰。
  • 策略規劃：深入了解關稅的影響，使客戶能夠就製造地、夥伴關係和打入市場策略做出明智的決策。

融合切片檢查市場報告要點

  • 融合切片檢查市場目前市場規模分析（2025 年）及 8 年市場預測（2026 年至 2034 年）
  • 過去三年發生的主要產品和技術開發、併購、合作和合資企業
  • 引領融合切片檢查市場的領導公司。
  • 融合切片檢查市場為其他競爭對手提供了各種機會。
  • 哪些細分市場在 2025 年表現最佳？這些細分市場在 2034 年的表現又會如何？
  • 目前融合切片檢查市場中哪些地區和國家表現最佳？
  • 企業應專注於哪些地區和國家，以尋求融合切片檢查市場的未來成長機會？

關於融合切片檢查市場的常見問題

1. 融合切片檢查市場的成長率是多少？

  • 預計從 2026 年到 2034 年的預測期內，融合切片檢查市場將以 7.40% 的複合年成長率成長。

2. 融合切片檢查的市場規模有多大？

  • 全球融合切片檢查市場預計將從 2025 年的 7.9836 億美元成長到 2034 年的 15.1232 億美元。

3. 融合切片檢查市場中哪個地區佔最大的市場佔有率？

  • 由於北美擁有先進的醫療基礎設施、磁振造影(MRI) 和超音波影像等創新影像技術的普及率高，以及前列腺癌發病率不斷上升，預計北美將成為融合切片檢查市場的主要驅動力。此外，主要市場參與者的存在、完善的保險報銷機制以及人們對早期準確癌症診斷重要性的日益重視，都進一步推動了融合切片檢查系統在全部區域的應用。

4. 融合切片檢查市場的成長要素為何？

  • 融合切片檢查市場的發展受到多種因素的共同推動：前列腺癌病例的增加、對精準早期診斷日益成長的需求、磁振造影(MRI) 和超音波影像等影像技術的不斷進步，以及公眾意識的提高和篩檢項目的擴展。隨著攝護腺癌發生率的上升，人們越來越需要能夠早期發現具有臨床意義腫瘤的精準診斷方案。同時，公眾意識的提高和廣泛的篩檢（例如 PSA 檢測和 MRI 檢查）也使得尋求明確診斷的患者數量不斷增加。融合切片檢查透過將先進的影像技術與標靶取樣相結合，滿足了這些需求，從而提高了診斷準確性並減少了不必要的手術。這些因素共同推動了融合切片檢查系統在醫療機構中的應用，並促進了整個市場的成長。

5. 融合切片檢查市場的主要企業有哪些？

  • 進入融合切片檢查市場的主要參與企業包括：皇家飛利浦公司、KOELIS SA、innoMedicus Ltd.、西門子醫療股份公司、MedCom GmbH、Exact Imaging Inc.、Focal Healthcare Inc.、Biobot Surgical Pte. Ltd.、Esaote SpA、GE HealthCare Technologies Inc.、日立醫療系統公司（醫療保健系統有限公司. Inc.、UroMedTech GmbH 和 D&K Technologies Pvt. Ltd.。

目錄

第1章：融合切片檢查市場報告概述

第2章：融合切片檢查市場摘要整理

  • 市場概覽

第3章：融合切片檢查市場關鍵因素分析

  • 融合切片檢查市場促進因素
  • 融合切片檢查市場的限制與挑戰
  • 融合切片檢查市場的機遇

第4章：影響分析

  • 人工智慧驅動的創新和應用
  • 美國關稅影響分析

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：融合切片檢查市場的波特五力分析

第7章：融合切片檢查市場評估

  • 依產品
  • 切片檢查途徑
  • 最終用戶
  • 按地區

第8章 競爭情勢

第9章：新創企業資金籌措與投資趨勢

第10章：融合切片檢查市場中的公司與產品概況

  • Koninklijke Philips NV
  • KOELIS SA
  • InnoMedicus Ltd.
  • Siemens Healthineers AG
  • edCom GmbH
  • Exact Imaging Inc.
  • Focal Healthcare Inc.
  • Biobot Surgical Pte. Ltd.
  • Esaote SpA
  • GE HealthCare Technologies Inc.
  • Hitachi Medical Systems (Hitachi, Ltd.)
  • Canon Medical Systems Corporation
  • BK Medical Holding Company, Inc
  • Eigen, Inc.
  • UroMedTech GmbH
  • D&K Technologies Pvt. Ltd.

第11章：KOL的觀點

第12章 專案方法

第13章：關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0916

Fusion Biopsy Market Summary

  • The global fusion biopsy market is expected to increase from USD 798.36 million in 2025 to USD 1,512.32 million by 2034, reflecting strong and sustained growth.
  • The global fusion biopsy market is growing at a CAGR of 7.40% during the forecast period from 2026 to 2034.
  • The fusion biopsy market is being significantly driven by the combined impact of rising cases of Prostate Cancer, increasing demand for accurate and early diagnosis, and continuous advancements in imaging technologies such as Magnetic Resonance Imaging (MRI) and ultrasound imaging, along with growing awareness and screening programs. As prostate cancer incidence increases, there is a greater need for precise diagnostic solutions that can detect clinically significant tumors at an early stage. At the same time, awareness initiatives and widespread screening (including PSA testing and MRI-based evaluation) are leading to higher patient inflow for confirmatory diagnostics. Fusion biopsy addresses these needs by combining advanced imaging with targeted sampling, thereby improving diagnostic accuracy and reducing unnecessary procedures. Collectively, these factors are accelerating the adoption of fusion biopsy systems across healthcare settings and boosting overall market growth.
  • The leading companies operating in the fusion biopsy market include Koninklijke Philips N.V., KOELIS S.A., innoMedicus Ltd., Siemens Healthineers AG, MedCom GmbH, Exact Imaging Inc., Focal Healthcare Inc., Biobot Surgical Pte. Ltd., Esaote S.p.A., GE HealthCare Technologies Inc., Hitachi Medical Systems (Hitachi, Ltd.), Canon Medical Systems Corporation, BK Medical Holding Company, Inc., Eigen, Inc., UroMedTech GmbH, D&K Technologies Pvt. Ltd., and others.
  • North America is expected to dominate the fusion biopsy market due to its advanced healthcare infrastructure, high adoption of innovative imaging technologies such as Magnetic Resonance Imaging (MRI) and Ultrasound Imaging, and the rising prevalence of Prostate Cancer. Additionally, the presence of leading market players, strong reimbursement frameworks, and increasing awareness regarding early and accurate cancer diagnosis are further driving the widespread adoption of fusion biopsy systems across the region.
  • In the product segment of the fusion biopsy market, the accessories category is estimated to account for the largest market share in 2025.

Factors Contributing to the Growth of the Fusion Biopsy Market

  • Rising prevalence of prostate cancer leading to a surge in fusion biopsy: One of the primary drivers is the increasing incidence of prostate cancer globally. Aging populations, lifestyle changes, and improved screening programs have led to higher diagnosis rates. Fusion biopsy plays a crucial role in accurately detecting clinically significant tumors, thereby driving its adoption among urologists and healthcare providers.
  • Growing demand for accurate and early diagnosis: Traditional biopsy methods often miss significant lesions due to random sampling. Fusion biopsy, which integrates MRI with ultrasound, significantly improves targeted detection. The demand for precision diagnostics and reducing false negatives is accelerating the shift toward fusion-guided techniques.
  • Advancements in imaging technologies: Rapid advancements in Magnetic Resonance Imaging (MRI) and ultrasound imaging have enabled high-resolution imaging and better lesion visualization. Integration of these technologies through software platforms has enhanced biopsy accuracy, boosting market growth.

Fusion Biopsy Market Report Segmentation

This fusion biopsy market report offers a comprehensive overview of the global fusion biopsy market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Products (Equipment and Consumables & Accessories), Route of Biopsy (Transrectal and Transperineal), End-Users (Hospitals, Diagnostic Imaging Centers, and Others), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing fusion biopsy market.

A fusion biopsy is an advanced diagnostic procedure that combines imaging techniques such as Magnetic Resonance Imaging (MRI) and Ultrasound Imaging to precisely locate and sample suspicious tissue, most commonly for detecting Prostate Cancer. By overlaying pre-recorded MRI images with real-time ultrasound during the procedure, it enables targeted biopsy of specific lesions, improving accuracy compared to traditional random biopsies and increasing the likelihood of detecting clinically significant cancers.

The fusion biopsy market is being significantly driven by the combined impact of rising cases of Prostate Cancer, increasing demand for accurate and early diagnosis, and continuous advancements in imaging technologies such as Magnetic Resonance Imaging (MRI) and Ultrasound Imaging, along with growing awareness and screening programs. As the incidence of prostate cancer continues to rise globally, particularly among the aging population, there is an urgent need for precise diagnostic solutions that can identify clinically significant tumors at an early and treatable stage. Traditional biopsy methods often lead to underdiagnosis or overdiagnosis due to random sampling, which has increased the preference for more targeted approaches like fusion biopsy.

At the same time, expanding awareness initiatives, government-led screening programs, and the widespread use of PSA testing and MRI-based evaluations are contributing to a higher volume of patients undergoing diagnostic procedures. This growing patient pool is directly increasing the demand for advanced biopsy techniques that can provide higher accuracy and reliability. Fusion biopsy effectively addresses these challenges by integrating high-resolution imaging with real-time guidance, enabling clinicians to precisely target suspicious lesions, improve cancer detection rates, and minimize unnecessary or repeat biopsies.

Furthermore, ongoing technological advancements, including the integration of software platforms, 3D imaging, and AI-assisted targeting, are enhancing procedural efficiency and clinical outcomes. These innovations not only improve physician confidence but also support better patient management and treatment planning. Collectively, these factors are accelerating the adoption of fusion biopsy systems across hospitals and diagnostic centers, thereby significantly boosting overall market growth.

What are the latest fusion biopsy market dynamics and trends?

The rising burden of prostate cancer worldwide is significantly boosting the overall market of fusion biopsy.

According to the data provided by the International Agency for Research on Cancer (2026), the estimated global new cases of prostate cancer would reach up to 18,29,988 by 2030. With the growing use of PSA (prostate-specific antigen) screening, a large number of suspected cases are being identified; however, traditional random biopsy methods often fail to accurately detect clinically significant tumors or may lead to overdiagnosis of indolent cancers. This limitation has created a strong demand for more precise and reliable diagnostic techniques. Fusion biopsy, which combines Magnetic Resonance Imaging (MRI) with Ultrasound Imaging, enables targeted sampling of suspicious lesions identified on MRI, thereby significantly improving detection rates of aggressive cancers while reducing unnecessary biopsies.

Additionally, the increasing awareness programs and early screening initiatives are playing a crucial role in boosting the fusion biopsy market by driving higher patient participation in cancer detection pathways and improving diagnostic accuracy. Campaigns focused on Prostate Cancer awareness, such as the American Cancer Society and the National Cancer Institute, encourage men, especially those at higher risk, to undergo regular PSA testing and clinical evaluations.

Additionally, the increasing product development activities and government initiatives are further boosting the overall market of fusion biopsy. For instance, in July 2024, Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, announced that the American Medical Association (AMA) introduced Category III Current Procedural Terminology (CPT) code 0898T to facilitate reimbursement for advanced AI-assisted prostate cancer mapping. Thus, the factors mentioned above are expected to boost the overall market of fusion biopsy during the forecast period.

However, the competition from alternative diagnostic techniques is acting as a limiting factor for the fusion biopsy market by offering less invasive, faster, and sometimes more cost-effective options for cancer detection. Emerging approaches such as Liquid Biopsy and advanced imaging-only diagnostics using Magnetic Resonance Imaging (MRI) are gaining traction as they reduce the need for invasive tissue sampling. These methods can detect cancer biomarkers through blood samples or provide high-resolution imaging insights, thereby minimizing patient discomfort and procedural risks. As healthcare systems increasingly focus on patient-friendly and cost-efficient diagnostics, the growing adoption of such alternatives may reduce the reliance on fusion biopsy procedures, ultimately restraining market growth.

Fusion Biopsy Market Segment Analysis

Fusion Biopsy Market by Products (Equipment and Consumables & Accessories), Route of Biopsy (Transrectal and Transperineal), End-Users (Hospitals, Diagnostic Imaging Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Fusion Biopsy Market Regional Analysis

North America Fusion Biopsy Market Trends

North America is expected to account for the highest proportion of 42.67% of the fusion biopsy market in 2025, out of all regions. North America is expected to dominate the fusion biopsy market due to its advanced healthcare infrastructure, high adoption of innovative imaging technologies such as Magnetic Resonance Imaging (MRI) and Ultrasound Imaging, and the rising prevalence of prostate cancer. Additionally, the presence of leading market players, strong reimbursement frameworks, and increasing awareness regarding early and accurate cancer diagnosis are further driving the widespread adoption of fusion biopsy systems across the region.

According to the data provided by the Zero Prostate Cancer Organization (2026), approximately 333,830 new cases of prostate cancer are expected to be diagnosed in 2026. Additionally, as per the same source, there are more than 3.5 million prostate cancer survivors in the U.S.

Fusion biopsy, which combines Magnetic Resonance Imaging (MRI) with Ultrasound Imaging, enables targeted sampling of suspicious lesions identified on MRI, thereby significantly improving detection rates of aggressive cancers while reducing unnecessary biopsies. Additionally, the increasing number of patients with prior negative biopsy results but persistently elevated PSA levels is further driving the adoption of fusion biopsy in North America, as it helps identify lesions that were previously missed. The shift toward personalized and precision medicine in oncology is also encouraging clinicians to adopt advanced diagnostic tools like fusion biopsy for better risk stratification and treatment planning.

However, the increase in product development activities among the key market players is further boosting the overall market. For instance, in July, 2025, Koninklijke Philips N.V. received FDA 510(k) clearance for the latest version of its UroNav fusion biopsy/navigation system, enhancing image-guided prostate cancer diagnosis with improved annotation workflows and precision targeting.

Collectively, these factors are expected to significantly drive the growth of the fusion biopsy market in the U.S. throughout the forecast period of 2026 to 2034.

Europe Fusion Biopsy Market Trends

The fusion biopsy market in Europe is witnessing strong and sustained growth due to the rising burden of Prostate Cancer, increasing adoption of advanced diagnostic technologies, and the strong presence of leading medical device manufacturers in the region. Countries such as Germany, the U.K., and France are investing heavily in precision diagnostics and imaging infrastructure, which is accelerating the adoption of fusion biopsy systems that integrate Magnetic Resonance Imaging (MRI) with Ultrasound Imaging for targeted cancer detection. Additionally, supportive clinical guidelines from European urology associations and growing awareness regarding early diagnosis are further contributing to market expansion. Recent product innovations and launches in the region are also strengthening market growth. For instance, in March, 2025, KOELIS showcased advanced enhancements to its Trinity(R) fusion biopsy platform at the European Association of Urology (EAU) Congress, focusing on improved workflow and targeted biopsy precision. Furthermore, in September, 2024, the company launched a new compact 3D transducer designed to enhance transperineal fusion biopsy procedures in Europe, while in April, 2026, it introduced AI-powered ProMap(R) Smart software to streamline MRI-ultrasound fusion workflows and improve clinical efficiency. Such continuous innovations, along with increasing clinical adoption and technological advancements, are collectively driving the robust growth of the fusion biopsy market across Europe.

Asia-Pacific Fusion Biopsy Market Trends

The Asia Pacific (APAC) region is emerging as a major growth driver for the fusion biopsy market due to the rapid expansion of healthcare infrastructure, increasing awareness of early cancer detection, and the rising prevalence of prostate cancer across countries such as China, India, and Japan. The region is witnessing significant investments in advanced diagnostic technologies, particularly systems integrating Magnetic Resonance Imaging (MRI) and Ultrasound Imaging, which are essential for fusion biopsy procedures. Additionally, growing government initiatives, improving access to healthcare services, and the rising adoption of minimally invasive diagnostics are contributing to higher demand for precision diagnostic tools. The increasing aging population in countries like Japan and South Korea further supports market growth, as prostate cancer risk rises with age.

Collectively, the combination of improving healthcare infrastructure, technological advancements, rising disease burden, and ongoing product innovations is accelerating the adoption of fusion biopsy systems in the Asia Pacific, making it one of the fastest-growing regions in the global market.

Who are the major players in the fusion biopsy market?

The following are the leading companies in the fusion biopsy market. These companies collectively hold the largest market share and dictate industry trends.

  • Koninklijke Philips N.V.
  • KOELIS S.A.
  • innoMedicus Ltd.
  • Siemens Healthineers AG
  • MedCom GmbH
  • Exact Imaging Inc.
  • Focal Healthcare Inc.
  • Biobot Surgical Pte. Ltd.
  • Esaote S.p.A.
  • GE HealthCare Technologies Inc.
  • Hitachi Medical Systems (Hitachi, Ltd.)
  • Canon Medical Systems Corporation
  • BK Medical Holding Company, Inc.,
  • igen, Inc.
  • UroMedTech GmbH
  • D&K Technologies Pvt. Ltd.
  • Others

How is the competitive landscape shaping the fusion biopsy market?

The competitive landscape of the fusion biopsy market is moderately consolidated yet highly dynamic, with a mix of global imaging giants and specialized urology-focused companies shaping industry growth. Leading players such as Koninklijke Philips N.V., GE HealthCare, and KOELIS hold a significant market share due to their strong portfolios in advanced imaging and fusion biopsy systems, while emerging players focus on niche innovations and regional expansion.

Competition is primarily driven by continuous technological innovation, including AI integration, robotic-assisted biopsy, and improved MRI ultrasound fusion platforms, as companies strive to enhance diagnostic accuracy and workflow efficiency. At the same time, firms are actively engaging in strategic initiatives such as product launches, partnerships, mergers, and collaborations to strengthen their global presence and expand into emerging markets.

Additionally, the presence of both established players and new entrants is intensifying competition, as startups introduce cost-effective and advanced solutions, while larger companies leverage their distribution networks and brand strength. This balance creates a competitive environment that fosters innovation and accelerates market growth. Overall, the evolving competitive landscape characterized by technological advancements, strategic expansion, and increasing participation of new players is significantly shaping the development and adoption of fusion biopsy technologies worldwide.

Recent Developmental Activities in the Fusion Biopsy Market

  • In April 2026, KOELIS introduced AI-powered ProMap(R) Smart software to streamline MRI-ultrasound fusion workflows and improve clinical efficiency.
  • In July, 2025, Koninklijke Philips N.V. received FDA 510(k) clearance for the latest version of its UroNav fusion biopsy/navigation system, enhancing image-guided prostate cancer diagnosis with improved annotation workflows and precision targeting.
  • In March 2025, the University of Oxford introduced a novel MRI-ultrasound fusion biopsy technique, aimed at reducing unnecessary biopsies and improving the detection of clinically significant prostate cancers.
  • In March, 2025, KOELIS showcased advanced enhancements to its Trinity(R) fusion biopsy platform at the European Association of Urology (EAU) Congress, focusing on improved workflow and targeted biopsy precision.

Fusion Biopsy Market Segmentation

  • Fusion Biopsy by Product Exposure
  • Equipment
  • Consumables & Accessories
  • Fusion Biopsy Route of Biopsy Exposure
  • Transrectal
  • Transperineal
  • Fusion Biopsy End-Users Exposure
  • Hospitals
  • Diagnostic Imaging Centres
  • Others
  • Fusion Biopsy Geography Exposure
  • North America Fusion Biopsy Market
  • United States Fusion Biopsy Market
  • Canada Fusion Biopsy Market
  • Mexico Fusion Biopsy Market
  • Europe Fusion Biopsy Market
  • United Kingdom Fusion Biopsy Market
  • Germany Fusion Biopsy Market
  • France Fusion Biopsy Market
  • Italy Fusion Biopsy Market
  • Spain Fusion Biopsy Market
  • Rest of Europe Fusion Biopsy Market
  • Asia-Pacific Fusion Biopsy Market
  • China Fusion Biopsy Market
  • Japan Fusion Biopsy Market
  • India Fusion Biopsy Market
  • Australia Fusion Biopsy Market
  • South Korea Fusion Biopsy Market
  • Rest of Asia-Pacific Fusion Biopsy Market
  • Rest of the World Fusion Biopsy Market
  • South America Fusion Biopsy Market
  • Middle East Fusion Biopsy Market
  • Africa Fusion Biopsy Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations are playing a transformative role in the evolution of fusion biopsy by significantly enhancing accuracy, efficiency, and clinical decision-making. Advanced artificial intelligence algorithms are increasingly being integrated with imaging modalities such as Magnetic Resonance Imaging (MRI) and Ultrasound Imaging to automatically detect, segment, and classify suspicious lesions, particularly in cases of Prostate Cancer. These systems assist radiologists by reducing interpretation variability and highlighting clinically significant regions that require targeted biopsy. AI is also being used for real-time image fusion optimization, ensuring precise alignment between MRI and ultrasound images during procedures, which improves needle targeting accuracy. Additionally, AI-driven predictive analytics and risk stratification tools analyze patient data, imaging findings, and historical outcomes to assess cancer aggressiveness and guide personalized treatment planning. Automation powered by AI further streamlines workflow by reducing procedure time, minimizing human error, and improving reproducibility across operators. As a result, AI-powered applications are not only enhancing diagnostic confidence but also accelerating the adoption of fusion biopsy systems by enabling more precise, efficient, and patient-centric cancer care.

U.S. Tariff Impact Analysis on Fusion Biopsy Market:

The U.S. tariff impact on the fusion biopsy market, which relies heavily on advanced medical devices and imaging systems, is largely negative and acts as a significant economic constraint. Fusion biopsy systems depend on high-value equipment such as Magnetic Resonance Imaging (MRI) and Ultrasound Imaging, many of which are manufactured or sourced globally. Recent U.S. tariff policies, including the April 2025 tariff expansion introducing baseline duties of around 10% and higher country-specific tariffs, have increased the cost of imported medical devices and components. As a result, healthcare providers face higher procurement costs, which can delay capital investments in expensive fusion biopsy systems. Additionally, since nearly 70% of medical devices used in the U.S. are manufactured overseas, tariffs significantly impact pricing and availability.

Furthermore, tariffs are disrupting global supply chains and creating uncertainty in equipment sourcing, leading hospitals to reconsider or postpone purchases of advanced diagnostic technologies. Increased costs may also be passed on to patients, reducing accessibility to advanced procedures like fusion biopsy. In response, manufacturers are being forced to adjust strategies, such as reshoring production or diversifying supply chains, which can increase operational complexity and slow innovation. Overall, U.S. tariffs are creating cost pressures, supply chain disruptions, and investment delays, thereby acting as a restraining factor for the growth and adoption of fusion biopsy technologies in the market.

How This Analysis Helps Clients

  • Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
  • Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
  • Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
  • Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the Fusion Biopsy market report study

  • Market size analysis for the current fusion biopsy market size (2025), and market forecast for 8 years (2026 to 2034)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the fusion biopsy market.
  • Various opportunities available for the other competitors in the fusion biopsy market space.
  • What are the top-performing segments in 2025? How these segments will perform in 2034?
  • Which are the top-performing regions and countries in the current fusion biopsy market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for the fusion biopsy market growth in the future.

Frequently Asked Questions for the Fusion Biopsy Market

1. What is the growth rate of the fusion biopsy market?

  • The fusion biopsy market is estimated to grow at a CAGR of 7.40% during the forecast period from 2026 to 2034.

2. What is the market for fusion biopsy?

  • The global fusion biopsy market is expected to increase from USD 798.36 million in 2025 to USD 1,512.32 million by 2034.

3. Which region has the highest share in the fusion biopsy market?

  • North America is expected to dominate the fusion biopsy market due to its advanced healthcare infrastructure, high adoption of innovative imaging technologies such as Magnetic Resonance Imaging (MRI) and Ultrasound Imaging, and the rising prevalence of Prostate Cancer. Additionally, the presence of leading market players, strong reimbursement frameworks, and increasing awareness regarding early and accurate cancer diagnosis are further driving the widespread adoption of fusion biopsy systems across the region.

4. What are the drivers for the fusion biopsy market?

  • The fusion biopsy market is being significantly driven by the combined impact of rising cases of prostate cancer, increasing demand for accurate and early diagnosis, and continuous advancements in imaging technologies such as Magnetic Resonance Imaging (MRI) and ultrasound imaging, along with growing awareness and screening programs. As prostate cancer incidence increases, there is a greater need for precise diagnostic solutions that can detect clinically significant tumors at an early stage. At the same time, awareness initiatives and widespread screening (including PSA testing and MRI-based evaluation) are leading to higher patient inflow for confirmatory diagnostics. Fusion biopsy addresses these needs by combining advanced imaging with targeted sampling, thereby improving diagnostic accuracy and reducing unnecessary procedures. Collectively, these factors are accelerating the adoption of fusion biopsy systems across healthcare settings and boosting overall market growth.

5. Who are the key players operating in the fusion biopsy market?

  • Some of the key market players operating in the fusion biopsy market include Koninklijke Philips N.V., KOELIS S.A., innoMedicus Ltd., Siemens Healthineers AG, MedCom GmbH, Exact Imaging Inc., Focal Healthcare Inc., Biobot Surgical Pte. Ltd., Esaote S.p.A., GE HealthCare Technologies Inc., Hitachi Medical Systems (Hitachi, Ltd.), Canon Medical Systems Corporation, BK Medical Holding Company, Inc., Eigen, Inc., UroMedTech GmbH, D&K Technologies Pvt. Ltd., and others.

Table of Contents

1. Fusion Biopsy Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumption

2. Fusion Biopsy Market Executive Summary

  • 2.1 Market at Glance

3. Fusion Biopsy Market Key Factors Analysis

  • 3.1 Fusion Biopsy Market Drivers
    • 3.1.1 Rising prevalence of prostate cancer
    • 3.1.2 Growing demand for accurate and early diagnosis
    • 3.1.3 Advancements in imaging technologies
  • 3.2 Fusion Biopsy Market Restraints and Challenges
    • 3.2.1 Competition from alternative diagnostic techniques
  • 3.3 Fusion Biopsy Market Opportunity
    • 3.3.1 Integration of advanced technologies such as artificial intelligence, robotics, and real-time imaging

4. Impact Analysis

  • 4.1 AI-Powered Innovations and Applications
  • 4.2 U.S. Tariff Impact Analysis

5. Regulatory Analysis

  • 5.1 The United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Fusion Biopsy Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Consumers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Fusion Biopsy Market Assessment

  • 7.1 By Product
    • 7.1.1 Equipment
    • 7.1.2 Consumables & Accessories
  • 7.2 By Route of Biopsy
    • 7.2.1 Transrectal
    • 7.2.2 Transperineal
  • 7.3 By End-Users
    • 7.3.1 Hospitals
    • 7.3.2 Diagnostic Imaging Centres
    • 7.3.3 Others
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 United States Fusion Biopsy Market Size in USD million (2023-2034)
      • 7.4.1.2 Canada Fusion Biopsy Market Size in USD million (2023-2034)
      • 7.4.1.3 Mexico Fusion Biopsy Market Size in USD million (2023-2034)
    • 7.4.2 Europe
      • 7.4.2.1 France Fusion Biopsy Market Size in USD million (2023-2034)
      • 7.4.2.2 Germany Fusion Biopsy Market Size in USD million (2023-2034)
      • 7.4.2.3 United Kingdom Fusion Biopsy Market Size in USD million (2023-2034)
      • 7.4.2.4 Italy Fusion Biopsy Market Size in USD million (2023-2034)
      • 7.4.2.5 Spain Fusion Biopsy Market Size in USD million (2023-2034)
      • 7.4.2.6 Rest of Europe Fusion Biopsy Market Size in USD million (2023-2034)
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 China Fusion Biopsy Market Size in USD million (2023-2034)
      • 7.4.3.2 Japan Fusion Biopsy Market Size in USD million (2023-2034)
      • 7.4.3.3 India Fusion Biopsy Market Size in USD million (2023-2034)
      • 7.4.3.4 Australia Fusion Biopsy Market Size in USD million (2023-2034)
      • 7.4.3.5 South Korea Fusion Biopsy Market Size in USD million (2023-2034)
      • 7.4.3.6 Rest of Asia-Pacific Fusion Biopsy Market Size in USD million (2023-2034)
    • 7.4.4 Rest of the World (RoW)
      • 7.4.4.1 Middle East Fusion Biopsy Market Size in USD million (2023-2034)
      • 7.4.4.2 Africa Fusion Biopsy Market Size in USD million (2023-2034)
      • 7.4.4.3 South America Fusion Biopsy Market Size In USD Million (2023-2034)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Fusion Biopsy Market Company and Product Profiles

  • 10.1 Koninklijke Philips N.V.
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Product Listing
    • 10.1.5 Entropy
  • 10.2 KOELIS S.A.
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Listing
    • 10.2.5 Entropy
  • 10.3 InnoMedicus Ltd.
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Listing
    • 10.3.5 Entropy
  • 10.4 Siemens Healthineers AG
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Listing
    • 10.4.5 Entropy
  • 10.5 edCom GmbH
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Listing
    • 10.5.5 Entropy
  • 10.6 Exact Imaging Inc.
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Listing
    • 10.6.5 Entropy
  • 10.7 Focal Healthcare Inc.
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Listing
    • 10.7.5 Entropy
  • 10.8 Biobot Surgical Pte. Ltd.
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Listing
    • 10.8.5 Entropy
  • 10.9 Esaote S.p.A.
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Listing
    • 10.9.5 Entropy
  • 10.10 GE HealthCare Technologies Inc.
    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Listing
    • 10.10.5 Entropy
  • 10.11 Hitachi Medical Systems (Hitachi, Ltd.)
    • 10.11.1 Company Overview
    • 10.11.2 Company Snapshot
    • 10.11.3 Financial Overview
    • 10.11.4 Product Listing
    • 10.11.5 Entropy
  • 10.12 Canon Medical Systems Corporation
    • 10.12.1 Company Overview
    • 10.12.2 Company Snapshot
    • 10.12.3 Financial Overview
    • 10.12.4 Product Listing
    • 10.12.5 Entropy
  • 10.13 BK Medical Holding Company, Inc.
    • 10.13.1 Company Overview
    • 10.13.2 Company Snapshot
    • 10.13.3 Financial Overview
    • 10.13.4 Product Listing
    • 10.13.5 Entrophy
  • 10.14 Eigen, Inc.
    • 10.14.1 Company Overview
    • 10.14.2 Company Snapshot
    • 10.14.3 Financial Overview
    • 10.14.4 Product Listing
    • 10.14.5 Entrophy
  • 10.15 UroMedTech GmbH
    • 10.15.1 Company Overview
    • 10.15.2 Company Snapshot
    • 10.15.3 Financial Overview
    • 10.15.4 Product Listing
    • 10.15.5 Entrophy
  • 10.16 D&K Technologies Pvt. Ltd.
    • 10.16.1 Company Overview
    • 10.16.2 Company Snapshot
    • 10.16.3 Financial Overview
    • 10.16.4 Product Listing
    • 10.16.5 Entrophy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us

List of Tables

  • Table 1: Fusion Biopsy Market in Global (2023-2034)
  • Table 2: Fusion Biopsy Market in Global by Product (2023-2034)
  • Table 3: Fusion Biopsy Market in Global by Route of Biopsy (2023-2034)
  • Table 4: Fusion Biopsy Market in Global by End-Users (2023-2034)
  • Table 5: Fusion Biopsy Market in Global by Geography (2023-2034)
  • Table 6: Fusion Biopsy Market in North America (2023-2034)
  • Table 7: Fusion Biopsy Market in the United States (2023-2034)
  • Table 8: Fusion Biopsy Market in Canada (2023-2034)
  • Table 9: Fusion Biopsy Market in Mexico (2023-2034)
  • Table 10: Fusion Biopsy Market in Europe (2023-2034)
  • Table 11: Fusion Biopsy Market in France (2023-2034)
  • Table 12: Fusion Biopsy Market in Germany (2023-2034)
  • Table 13: Fusion Biopsy Market in United Kingdom (2023-2034)
  • Table 14: Fusion Biopsy Market in Italy (2023-2034)
  • Table 15: Fusion Biopsy Market in Spain (2023-2034)
  • Table 16: Fusion Biopsy Market in the Rest of Europe (2023-2034)
  • Table 17: Fusion Biopsy Market in Asia-Pacific (2023-2034)
  • Table 18: Fusion Biopsy Market in China (2023-2034)
  • Table 19: Fusion Biopsy Market in Japan (2023-2034)
  • Table 20: Fusion Biopsy Market in India (2023-2034)
  • Table 21: Fusion Biopsy Market in Australia (2023-2034)
  • Table 22: Fusion Biopsy Market in South Korea (2023-2034)
  • Table 23: Fusion Biopsy Market in Rest of Asia-Pacific (2023-2034)
  • Table 24: Fusion Biopsy Market in the Rest of the World (2023-2034)
  • Table 25: Fusion Biopsy Market in the Middle East (2023-2034)
  • Table 26: Fusion Biopsy Market in Africa (2023-2034)
  • Table 27: Fusion Biopsy Market in South America (2023-2034)
  • Table 28: Competitive Landscape
  • Table 29: Startup Funding & Investment Trends

List of Figures

  • Figure 1: Fusion Biopsy Market Drivers
  • Figure 2: Fusion Biopsy Market Restraints
  • Figure 3: Fusion Biopsy Market Opportunities
  • Figure 4: AI-Powered Innovations in Fusion Biopsy Market
  • Figure 5: US Tariff Impact on Fusion Biopsy Market
  • Figure 6: Regulatory Analysis (US, EU, Japan, China)
  • Figure 7: Porter's Five Forces Analysis
  • Figure 8: Competitive Analysis
  • Figure 9: Fusion Biopsy Market in Global (2023-2034)
  • Figure 10: Fusion Biopsy Market in Global by Product (2023-2034)
  • Figure 11: Fusion Biopsy Market in Global by Route of Biopsy (2023-2034)
  • Figure 12: Fusion Biopsy Market in Global by End-Users (2023-2034)
  • Figure 13: Fusion Biopsy Market in Global by Geography (2023-2034)
  • Figure 14: Fusion Biopsy Market in North America (2023-2034)
  • Figure 15: Fusion Biopsy Market in the United States (2023-2034)
  • Figure 16: Fusion Biopsy Market in Canada (2023-2034)
  • Figure 17: Fusion Biopsy Market in Mexico (2023-2034)
  • Figure 18: Fusion Biopsy Market in Europe (2023-2034)
  • Figure 19: Fusion Biopsy Market in France (2023-2034)
  • Figure 20: Fusion Biopsy Market in Germany (2023-2034)
  • Figure 21: Fusion Biopsy Market in United Kingdom (2023-2034)
  • Figure 22: Fusion Biopsy Market in Italy (2023-2034)
  • Figure 23: Fusion Biopsy Market in Spain (2023-2034)
  • Figure 24: Fusion Biopsy Market in the Rest of Europe (2023-2034)
  • Figure 25: Fusion Biopsy Market in Asia-Pacific (2023-2034)
  • Figure 26: Fusion Biopsy Market in China (2023-2034)
  • Figure 27: Fusion Biopsy Market in Japan (2023-2034)
  • Figure 28: Fusion Biopsy Market in India (2023-2034)
  • Figure 29: Fusion Biopsy Market in Australia (2023-2034)
  • Figure 30: Fusion Biopsy Market in South Korea (2023-2034)
  • Figure 31: Fusion Biopsy Market in Rest of Asia-Pacific (2023-2034)
  • Figure 32: Fusion Biopsy Market in the Rest of the World (2023-2034)
  • Figure 33: Fusion Biopsy Market in the Middle East (2023-2034)
  • Figure 34: Fusion Biopsy Market in Africa (2023-2034)
  • Figure 35: Fusion Biopsy Market in South America (2023-2034)
  • Figure 36: Competitive Landscape
  • Figure 39: Startup Funding & Investment Trends